Bank Of Montreal

Direxion Daily Small Cap Bull 3X ETF

SPDR S&P Retail ETF

ProShares UltraPro Dow30

ProShares UltraShort Bloomberg Natrl Gas

Guggenheim Solar ETF

Direxion Technology Bear 3X Shares

Materials Select Sector SPDR

ProShares Trust ProShares Short Bitcoin Strategy ETF

ProShares Bitcoin Strategy ETF

Direxion Daily Small Cap Bear 3X ETF

ProShares Ultra Bloomberg Natural Gas

Direxion Daily Technology Bull 3X ETF

ARK Innovation ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Magal Security Systems Ltd.

Direxion Financial Bear 3X Shar

Direxion Daily Semicondct Bull 3X ETF

JELD-WEN Holding Inc. Common Stock

Las Vegas Sands Corp. Common Stock

Century Communities Inc. Common Stock

Kontoor Brands Inc. Common Stock

Bath & Body Works Inc.

RLJ Lodging Trust Common Shares of Beneficial Interest $0.01 par value

Leggett & Platt Incorporated Common Stock

Snap Inc. Class A Common Stock

Cleveland-Cliffs Inc. Common Stock

Civitas Resources Inc. Common Stock

Archer Aviation Inc. Class A Common Stock

AMC Entertainment Holdings Inc. Class A Common Stock

Oklo Inc.

QuantumScape Corporation Class A Common Stock

Sea Limited American Depositary Shares each representing one Class A Ordinary Share

Cameco Corporation Common Stock

Twilio Inc. Class A Common Stock

Spotify Technology S.A. Ordinary Shares

Cloudflare Inc. Class A Common Stock

Molina Healthcare Inc Common Stock

Click here to get full coverage on MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout - Yahoo Finance

MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout  Yahoo Finance

MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout - Yahoo Finance

Click here to get full coverage on MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest (MLTX) - Seeking Alpha

MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest (MLTX)  Seeking Alpha

MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest (MLTX) - Seeking Alpha

Click here to get full coverage on Wolfe Research Upgrades MoonLake Immunotherapeutics (MLTX) - Nasdaq

Wolfe Research Upgrades MoonLake Immunotherapeutics (MLTX)  Nasdaq

Wolfe Research Upgrades MoonLake Immunotherapeutics (MLTX) - Nasdaq

Click here to get full coverage on Learn to Evaluate (MLTX) using the Charts - news.stocktradersdaily.com

Learn to Evaluate (MLTX) using the Charts  news.stocktradersdaily.com

Learn to Evaluate (MLTX) using the Charts - news.stocktradersdaily.com

Click here to get full coverage on MoonLake Lands Massive $500M Deal: Game-Changing Clinical Updates Coming April 29 - Stock Titan

MoonLake Lands Massive $500M Deal: Game-Changing Clinical Updates Coming April 29  Stock Titan

MoonLake Lands Massive $500M Deal: Game-Changing Clinical Updates Coming April 29 - Stock Titan

Click here to get full coverage on Merck held talks to buy biotech MoonLake for over $3 billion, FT reports - Reuters

Merck held talks to buy biotech MoonLake for over $3 billion, FT reports  Reuters

Merck held talks to buy biotech MoonLake for over $3 billion, FT reports - Reuters

Click here to get full coverage on We Think MoonLake Immunotherapeutics (NASDAQ:MLTX) Can Afford To Drive Business Growth - simplywall.st

We Think MoonLake Immunotherapeutics (NASDAQ:MLTX) Can Afford To Drive Business Growth  simplywall.st

We Think MoonLake Immunotherapeutics (NASDAQ:MLTX) Can Afford To Drive Business Growth - simplywall.st

Click here to get full coverage on MoonLake Immunotherapeutics Catapults On Rumored $3 Billion Merck Takeover Bid - Investor's Business Daily

MoonLake Immunotherapeutics Catapults On Rumored $3 Billion Merck Takeover Bid  Investor's Business Daily

MoonLake Immunotherapeutics Catapults On Rumored $3 Billion Merck Takeover Bid - Investor's Business Daily

Click here to get full coverage on MoonLake's (MLTX) 'Outperform' Rating Reiterated by RBC Capital | MLTX Stock News - GuruFocus

MoonLake's (MLTX) 'Outperform' Rating Reiterated by RBC Capital | MLTX Stock News  GuruFocus

MoonLake's (MLTX) 'Outperform' Rating Reiterated by RBC Capital | MLTX Stock News - GuruFocus

Click here to get full coverage on StockWatch: Report of $3B+ Merck Buyout Offer Propels MoonLake Stock Surge - Genetic Engineering and Biotechnology News

StockWatch: Report of $3B+ Merck Buyout Offer Propels MoonLake Stock Surge  Genetic Engineering and Biotechnology News

StockWatch: Report of $3B+ Merck Buyout Offer Propels MoonLake Stock Surge - Genetic Engineering and Biotechnology News

Click here to get full coverage on Merck and MoonLake: A Strategic Imperative for Biopharma Dominance - AInvest

Merck and MoonLake: A Strategic Imperative for Biopharma Dominance  AInvest

Merck and MoonLake: A Strategic Imperative for Biopharma Dominance - AInvest

Click here to get full coverage on MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update - GlobeNewswire

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update  GlobeNewswire

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update - GlobeNewswire

Click here to get full coverage on MoonLake Immunotherapeutics Breaks Above 200-Day Moving Average - Bullish for MLTX - Nasdaq

MoonLake Immunotherapeutics Breaks Above 200-Day Moving Average - Bullish for MLTX  Nasdaq

MoonLake Immunotherapeutics Breaks Above 200-Day Moving Average - Bullish for MLTX - Nasdaq

Click here to get full coverage on Long Term Trading Analysis for (MLTX) - news.stocktradersdaily.com

Long Term Trading Analysis for (MLTX)  news.stocktradersdaily.com

Long Term Trading Analysis for (MLTX) - news.stocktradersdaily.com

Click here to get full coverage on Merck Eyes Potential Acquisition of MoonLake Immunotherapeutics (MLTX) | MLTX Stock News - GuruFocus

Merck Eyes Potential Acquisition of MoonLake Immunotherapeutics (MLTX) | MLTX Stock News  GuruFocus

Merck Eyes Potential Acquisition of MoonLake Immunotherapeutics (MLTX) | MLTX Stock News - GuruFocus

Click here to get full coverage on MoonLake Immunotherapeutics: A Buy At Dips (NASDAQ:MLTX) - Seeking Alpha

MoonLake Immunotherapeutics: A Buy At Dips (NASDAQ:MLTX)  Seeking Alpha

MoonLake Immunotherapeutics: A Buy At Dips (NASDAQ:MLTX) - Seeking Alpha

Click here to get full coverage on Merck's (MRK) Acquisition Offer Boosts MoonLake (MLTX) Shares - GuruFocus

Merck's (MRK) Acquisition Offer Boosts MoonLake (MLTX) Shares  GuruFocus

Merck's (MRK) Acquisition Offer Boosts MoonLake (MLTX) Shares - GuruFocus

Click here to get full coverage on MoonLake Immunotherapeutics (MLTX) Hosts Investor Meetings Amid Merger Speculation | MLTX Stock News - GuruFocus

MoonLake Immunotherapeutics (MLTX) Hosts Investor Meetings Amid Merger Speculation | MLTX Stock News  GuruFocus

MoonLake Immunotherapeutics (MLTX) Hosts Investor Meetings Amid Merger Speculation | MLTX Stock News - GuruFocus

Click here to get full coverage on MoonLake Immunotherapeutics Elects Directors at AGM - TipRanks

MoonLake Immunotherapeutics Elects Directors at AGM  TipRanks

MoonLake Immunotherapeutics Elects Directors at AGM - TipRanks

Click here to get full coverage on MoonLake Immunotherapeutics Unveiled: A Tale of Market Growth - StocksToTrade

MoonLake Immunotherapeutics Unveiled: A Tale of Market Growth  StocksToTrade

MoonLake Immunotherapeutics Unveiled: A Tale of Market Growth - StocksToTrade

Click here to get full coverage on MoonLake Immunotherapeutics (MLTX) Surges 25% on Merck Acquisiti - GuruFocus

MoonLake Immunotherapeutics (MLTX) Surges 25% on Merck Acquisiti  GuruFocus

MoonLake Immunotherapeutics (MLTX) Surges 25% on Merck Acquisiti - GuruFocus

Click here to get full coverage on Merck (MRK) Held Talks To Buy MoonLake Immunotherapeutics (MLTX) - FT - StreetInsider

Merck (MRK) Held Talks To Buy MoonLake Immunotherapeutics (MLTX) - FT  StreetInsider

Merck (MRK) Held Talks To Buy MoonLake Immunotherapeutics (MLTX) - FT - StreetInsider

Click here to get full coverage on Is MoonLake Immunotherapeutics (MLTX) Among the Best Guru Stocks to Buy According to Wall Street Analysts? - Insider Monkey

Is MoonLake Immunotherapeutics (MLTX) Among the Best Guru Stocks to Buy According to Wall Street Analysts?  Insider Monkey

Is MoonLake Immunotherapeutics (MLTX) Among the Best Guru Stocks to Buy According to Wall Street Analysts? - Insider Monkey

Click here to get full coverage on Stat’s Feuerstein says ‘no imminent acquisition’ of MoonLake Immunotherapeutics - TipRanks

Stat’s Feuerstein says ‘no imminent acquisition’ of MoonLake Immunotherapeutics  TipRanks

Stat’s Feuerstein says ‘no imminent acquisition’ of MoonLake Immunotherapeutics - TipRanks

Click here to get full coverage on Merck made $3B+ offer for MoonLake earlier this year - report (MRK:NYSE) - Seeking Alpha

Merck made $3B+ offer for MoonLake earlier this year - report (MRK:NYSE)  Seeking Alpha

Merck made $3B+ offer for MoonLake earlier this year - report (MRK:NYSE) - Seeking Alpha

Click here to get full coverage on How the (MLTX) price action is used to our Advantage - news.stocktradersdaily.com

How the (MLTX) price action is used to our Advantage  news.stocktradersdaily.com

How the (MLTX) price action is used to our Advantage - news.stocktradersdaily.com

Click here to get full coverage on Merck's Bold Proposal Sends MoonLake's Shares Climbing - Finimize

Merck's Bold Proposal Sends MoonLake's Shares Climbing  Finimize

Merck's Bold Proposal Sends MoonLake's Shares Climbing - Finimize

Click here to get full coverage on MoonLake Immunotherapeutics: A Somewhat Complicated Story (NASDAQ:MLTX) - Seeking Alpha

MoonLake Immunotherapeutics: A Somewhat Complicated Story (NASDAQ:MLTX)  Seeking Alpha

MoonLake Immunotherapeutics: A Somewhat Complicated Story (NASDAQ:MLTX) - Seeking Alpha

Click here to get full coverage on MoonLake Immunotherapeutics: A Breakout Play on the Cusp of a $100 Run? - AInvest

MoonLake Immunotherapeutics: A Breakout Play on the Cusp of a $100 Run?  AInvest

MoonLake Immunotherapeutics: A Breakout Play on the Cusp of a $100 Run? - AInvest

Click here to get full coverage on MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update - GlobeNewswire

MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update  GlobeNewswire

MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update - GlobeNewswire

Click here to get full coverage on RBC Capital maintains outperform rating on Moonlake stock - Investing.com

RBC Capital maintains outperform rating on Moonlake stock  Investing.com

RBC Capital maintains outperform rating on Moonlake stock - Investing.com

Click here to get full coverage on MoonLake secures up to $500 million financing; research update - The Pharma Letter

MoonLake secures up to $500 million financing; research update  The Pharma Letter

MoonLake secures up to $500 million financing; research update - The Pharma Letter

Click here to get full coverage on MoonLake Shares Jump On Potential Merck Acquisition Offer - Finimize

MoonLake Shares Jump On Potential Merck Acquisition Offer  Finimize

MoonLake Shares Jump On Potential Merck Acquisition Offer - Finimize

Click here to get full coverage on Guggenheim reaffirms Buy rating on Moonlake stock amid M&A talks - Investing.com

Guggenheim reaffirms Buy rating on Moonlake stock amid M&A talks  Investing.com

Guggenheim reaffirms Buy rating on Moonlake stock amid M&A talks - Investing.com

Click here to get full coverage on Merck held talks to buy Swiss biotech MoonLake for more than $3bn - Financial Times

Merck held talks to buy Swiss biotech MoonLake for more than $3bn  Financial Times

Merck held talks to buy Swiss biotech MoonLake for more than $3bn - Financial Times

Click here to get full coverage on Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report - Yahoo Finance

Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report  Yahoo Finance

Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report - Yahoo Finance

Click here to get full coverage on MoonLake and Merck: A $3 Billion Opportunity to Beat the Patent Clock - AInvest

MoonLake and Merck: A $3 Billion Opportunity to Beat the Patent Clock  AInvest

MoonLake and Merck: A $3 Billion Opportunity to Beat the Patent Clock - AInvest

Click here to get full coverage on H.C. Wainwright maintains $100 target on Moonlake stock - Investing.com

H.C. Wainwright maintains $100 target on Moonlake stock  Investing.com

H.C. Wainwright maintains $100 target on Moonlake stock - Investing.com

Click here to get full coverage on MoonLake Immunotherapeutics stock surges on FT report of Merck buyout talks - Investing.com Canada

MoonLake Immunotherapeutics stock surges on FT report of Merck buyout talks  Investing.com Canada

MoonLake Immunotherapeutics stock surges on FT report of Merck buyout talks - Investing.com Canada

Click here to get full coverage on Wolfe Research lifts Moonlake stock to Outperform - Investing.com

Wolfe Research lifts Moonlake stock to Outperform  Investing.com

Wolfe Research lifts Moonlake stock to Outperform - Investing.com

Click here to get full coverage on MoonLake’s CEO on its looming mid-year pivotal readout in skin disease - Endpoints News

MoonLake’s CEO on its looming mid-year pivotal readout in skin disease  Endpoints News

MoonLake’s CEO on its looming mid-year pivotal readout in skin disease - Endpoints News

Click here to get full coverage on MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11 - Finansavisen

MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11  Finansavisen

MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11 - Finansavisen

Click here to get full coverage on MLTX Factor-Based Stock Analysis - Nasdaq

MLTX Factor-Based Stock Analysis  Nasdaq

MLTX Factor-Based Stock Analysis - Nasdaq

Click here to get full coverage on How A Rival's Flop — And 54% Crash — Sent This Top Biotech Flying - Investor's Business Daily

How A Rival's Flop — And 54% Crash — Sent This Top Biotech Flying  Investor's Business Daily

How A Rival's Flop — And 54% Crash — Sent This Top Biotech Flying - Investor's Business Daily

Click here to get full coverage on Barclays Maintains MoonLake Immunotherapeutics - (MLTX) Equal-Weight Recommendation - Nasdaq

Barclays Maintains MoonLake Immunotherapeutics - (MLTX) Equal-Weight Recommendation  Nasdaq

Barclays Maintains MoonLake Immunotherapeutics - (MLTX) Equal-Weight Recommendation - Nasdaq

Click here to get full coverage on Exclusive: MoonLake Immunotherapeutics explores sale, sources say - Reuters

Exclusive: MoonLake Immunotherapeutics explores sale, sources say  Reuters

Exclusive: MoonLake Immunotherapeutics explores sale, sources say - Reuters

Click here to get full coverage on MoonLake Immunotherapeutics (MLTX) Stock Price, News & Analysis - MarketBeat

MoonLake Immunotherapeutics (MLTX) Stock Price, News & Analysis  MarketBeat

MoonLake Immunotherapeutics (MLTX) Stock Price, News & Analysis - MarketBeat

Click here to get full coverage on MoonLake Immunotherapeutics AG and Helix Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing Tri-specific Nanobody® Sonelokimab - Business Wire

MoonLake Immunotherapeutics AG and Helix Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing Tri-specific Nanobody® Sonelokimab  Business Wire

MoonLake Immunotherapeutics AG and Helix Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing Tri-specific Nanobody® Sonelokimab - Business Wire

Click here to get full coverage on MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares - GlobeNewswire

MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares  GlobeNewswire

MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares - GlobeNewswire

Click here to get full coverage on What Is The Ownership Structure Like For MoonLake Immunotherapeutics (NASDAQ:MLTX)? - Nasdaq

What Is The Ownership Structure Like For MoonLake Immunotherapeutics (NASDAQ:MLTX)?  Nasdaq

What Is The Ownership Structure Like For MoonLake Immunotherapeutics (NASDAQ:MLTX)? - Nasdaq

Click here to get full coverage on MoonLake Immunotherapeutics announces landmark Phase 2 - GlobeNewswire

MoonLake Immunotherapeutics announces landmark Phase 2  GlobeNewswire

MoonLake Immunotherapeutics announces landmark Phase 2 - GlobeNewswire

Click here to get full coverage on Post-Lilly deal for Dice, Moonlake phase II win in HS reflects IL-17’s continuing spell - BioWorld MedTech

Post-Lilly deal for Dice, Moonlake phase II win in HS reflects IL-17’s continuing spell  BioWorld MedTech

Post-Lilly deal for Dice, Moonlake phase II win in HS reflects IL-17’s continuing spell - BioWorld MedTech

Click here to get full coverage on MoonLake over the moon with $230M SPAC deal for llama antibodies to challenge Novartis' Cosentyx - Fierce Biotech

MoonLake over the moon with $230M SPAC deal for llama antibodies to challenge Novartis' Cosentyx  Fierce Biotech

MoonLake over the moon with $230M SPAC deal for llama antibodies to challenge Novartis' Cosentyx - Fierce Biotech

Click here to get full coverage on MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC  Defense World

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World

Click here to get full coverage on Tuesday’s Top-Performing Stocks: MLTX & FERG Rise Double-Digits - Watcher Guru

Tuesday’s Top-Performing Stocks: MLTX & FERG Rise Double-Digits  Watcher Guru

MoonLake Immunotherapeutics (MLTX)

Price Chart

Key Statistics

Technicals

About MLTX

Latest News

MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout - Yahoo Finance

MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest (MLTX) - Seeking Alpha

Wolfe Research Upgrades MoonLake Immunotherapeutics (MLTX) - Nasdaq

Advanced Charts

Top Gainers

Top Losers